INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100,814,048 | -19.4% | 1,935,382 | -2.0% | 0.03% | -18.2% |
| Q2 2023 | $125,049,465 | +27.0% | 1,974,881 | +8.6% | 0.03% | +22.2% |
| Q1 2023 | $98,487,587 | +4.8% | 1,818,792 | +2.4% | 0.03% | -3.6% |
| Q4 2022 | $93,987,560 | +20.0% | 1,776,031 | +5.5% | 0.03% | +12.0% |
| Q3 2022 | $78,300,000 | +68.1% | 1,682,793 | +106.2% | 0.02% | +78.6% |
| Q2 2022 | $46,587,000 | +59.2% | 816,187 | +70.6% | 0.01% | +100.0% |
| Q1 2022 | $29,272,000 | +1623.9% | 478,385 | +1374.7% | 0.01% | – |
| Q4 2021 | $1,698,000 | +33.2% | 32,440 | -5.1% | 0.00% | – |
| Q3 2021 | $1,275,000 | -87.7% | 34,197 | -86.5% | 0.00% | -100.0% |
| Q2 2021 | $10,355,000 | +0.7% | 253,678 | -16.3% | 0.00% | 0.0% |
| Q1 2021 | $10,287,000 | +1344.8% | 303,174 | +1255.0% | 0.00% | – |
| Q4 2020 | $712,000 | -89.3% | 22,374 | -91.4% | 0.00% | -100.0% |
| Q3 2020 | $6,681,000 | -0.8% | 260,372 | -0.7% | 0.00% | 0.0% |
| Q2 2020 | $6,732,000 | +49.2% | 262,274 | -10.7% | 0.00% | 0.0% |
| Q1 2020 | $4,512,000 | +317.0% | 293,539 | +830.3% | 0.00% | – |
| Q4 2019 | $1,082,000 | +314.6% | 31,553 | -10.0% | 0.00% | – |
| Q3 2019 | $261,000 | -40.4% | 35,045 | +3.8% | 0.00% | – |
| Q2 2019 | $438,000 | +13.5% | 33,761 | +6.5% | 0.00% | – |
| Q1 2019 | $386,000 | +73.9% | 31,701 | +62.7% | 0.00% | – |
| Q4 2018 | $222,000 | -49.5% | 19,479 | -4.0% | 0.00% | – |
| Q3 2018 | $440,000 | +25.7% | 20,281 | +2.5% | 0.00% | – |
| Q2 2018 | $350,000 | -54.6% | 19,795 | -45.9% | 0.00% | – |
| Q1 2018 | $771,000 | -45.4% | 36,621 | -62.5% | 0.00% | -100.0% |
| Q4 2017 | $1,413,000 | +93.8% | 97,610 | +111.3% | 0.00% | – |
| Q3 2017 | $729,000 | +29.9% | 46,196 | +2.3% | 0.00% | – |
| Q2 2017 | $561,000 | +24.7% | 45,176 | +63.0% | 0.00% | – |
| Q1 2017 | $450,000 | -75.6% | 27,721 | -58.3% | 0.00% | -100.0% |
| Q1 2016 | $1,848,000 | -74.9% | 66,475 | -51.4% | 0.00% | -66.7% |
| Q4 2015 | $7,363,000 | +41.0% | 136,875 | +5.0% | 0.00% | +50.0% |
| Q3 2015 | $5,221,000 | +6955.4% | 130,389 | +5508.1% | 0.00% | – |
| Q2 2015 | $74,000 | – | 2,325 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |